Zevra Therapeutics Inc (ZVRA)

Apr 17, 2025, 7:30 AM EDT - 9 days ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 19 days ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 26 days ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 6 weeks ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 6 weeks ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 2 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 2 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 2 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 2 months ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 3 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 3 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 3 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 4 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 5 months ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 5 months ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 5 months ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 6 months ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 6 months ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 7 months ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 7 months ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 7 months ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 7 months ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 8 months ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 9 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 9 months ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Aug 8, 2024, 4:01 PM EDT - 9 months ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Aug 7, 2024, 9:34 AM EDT - 9 months ago

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 5:50 PM EDT - 9 months ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Jul 30, 2024, 8:38 AM EDT - 9 months ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Jun 25, 2024, 7:30 AM EDT - 10 months ago

Zevra Therapeutics Expands Executive Leadership Team

Jun 18, 2024, 7:30 AM EDT - 11 months ago

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Jun 3, 2024, 11:00 AM EDT - 11 months ago

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

May 8, 2024, 2:53 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

Apr 15, 2024, 5:01 PM EDT - 1 year ago

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

Apr 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

Mar 28, 2024, 10:25 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:32 PM EDT - 1 year ago

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Mar 26, 2024, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

Mar 4, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Feb 6, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 23, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

Jan 8, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Jan 4, 2024, 8:55 AM EST - 1 year ago

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer